The US Court of Appeals for the Federal Circuit has refused Novartis’s bid to block generic versions of its Gilenya (fingolimod) blockbuster treatment for multiple sclerosis from launching while it takes its legal fight against ANDA sponsor HEC Pharm to the US Supreme Court.
In a 27 September ruling, the Federal Circuit denied the originator’s petition to stay issuance of its mandate of a...




